BridgeBio Oncology Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Operating income | -$145.8 | -$80.9 | -$<0.1 | — |
| Net income | -$134.0 | -$74.3 | -$<0.1 | — |
| Cash Flow Statement | ||||
| Free cash flow | -$114.5 | -$55.1 | — | — |
Shares outstanding 80.2M · Free float 23.9%
Annual filing data through FY ended December 31, 2025; float as of September 13, 2026.